810MO Patient-reported outcomes (PROs) in patients (pts) receiving niraparib in the PRIMA/ENGOT-OV26/GOG-3012 trial

Abstract

Open access

Peer reviewed

B. Pothuri, S. Han, D. Chase, F. Heitz, R. Burger, L. Gaba, L. Van Le, E. Guerra, D. Bender, J. Korach, …

Annals of oncology, Vol.31, pp.S612-S613

09/2020

DOI: 10.1016/j.annonc.2020.08.949

Files and links (1)

url

https://doi.org/10.1016/j.annonc.2020.08.949View

Published (Version of record) Open Access

Title: Subtitle: 810MO Patient-reported outcomes (PROs) in patients (pts) receiving niraparib in the PRIMA/ENGOT-OV26/GOG-3012 trial
Creators: B. Pothuri - Gynecologic Oncology Group
S. Han - KU Leuven
D. Chase - University of Arizona
F. Heitz - Kliniken Essen-Mitte
R. Burger - University of Pennsylvania
L. Gaba - Hospital Clínic de Barcelona
L. Van Le - University of North Carolina at Chapel Hill
E. Guerra - Hospital Universitario Ramón y Cajal
D. Bender - University of Iowa
J. Korach - Sheba Medical Center
N.G. Cloven - Texas Oncology
P. Follana - Centre Antoine Lacassagne
J-F. Baurain - Cliniques Universitaires Saint-Luc
C. Pisano - Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"
U. Peen - Herlev Hospital
J. Maenpaa - Tampere University Hospital
E. Bacqué - GlaxoSmithKline
Y. Li - GlaxoSmithKline (Italy)
A González Martin - Clinica Universidad de Navarra
B.J. Monk - University of Arizona
Resource Type: Abstract
Publication Details: Annals of oncology, Vol.31, pp.S612-S613
DOI: 10.1016/j.annonc.2020.08.949
ISSN: 0923-7534
eISSN: 1569-8041
Publisher: Elsevier Ltd
Grant note: DOI: 10.13039/100005620, name: North Carolina GlaxoSmithKline Foundation
Language: English
Date published: 09/2020
Academic Unit: Obstetrics and Gynecology
Record Identifier: 9984317110402771

65 Record Views